Search

TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of action in preclinical [...]

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected [...]

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of [...]

CHESTERBROOK, Pa: Trevena, Inc. has issued the following news release: Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central [...]

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 [...]

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and [...]

CHESTERBROOK: Trevena, Inc has issued the following press release: Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous [...]

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial [...]

OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilutive tranche from R-Bridge upon [...]

CHESTERBROOK, Pa: Trevena, Inc. has issued the following news release: Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central [...]

Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study TRV045, a novel S1P receptor modulator, continues [...]

New York: Trevena, Inc. has issued the following news release: OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, [...]

OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement Positive Phase 1 topline results for TRV045, a novel S1P receptor modulator; no serious adverse events and [...]

Chesterbrook: Trevena, Inc. (TRVN) has issued the following press release: Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous [...]

CHESTERBROOK, Pa., Aug 11, 2022 (GLOBE NEWSWIRE via COMTEX) -- OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study Phase 1 [...]

CHESTERBROOK: Trevena, Inc. has issued the following news release: Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system [...]

CHESTERBROOK, May 11, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:TRVN), EQNX::TICKER_END OLINVYK refocused commercial strategy initiated mid-Q1 OLINVYK respiratory physiology study demonstrated statistically significant reduced impact on respiratory function [...]

CHESTERBROOK, Pa., Nov 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:TRVN), EQNX::TICKER_END -- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK [...]

CHESTERBROOK, Pa., Aug 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 [...]

CHESTERBROOK, May 06, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Company reaffirms YE target of 100 formulary approvals for OLINVYK(R) Announces new OLINVYK clinical outcomes study to further examine potential [...]

CHESTERBROOK, Mar 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- OLINVYK(TM) approved in U.S.; customer-facing teams now fully deployed Primary study completion for TRV027 in COVID-19 patients expected in 1H [...]